Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2000

View Archived Issues

Pain Therapeutics discusses product pipeline at investors conference

Human Akt3 and its use in gene therapy disclosed by Aventis

Millennium and Bayer move 70+ drug targets into high-throughput screening

Human Genome Sciences and CAT enter anti-BLyS antibody alliance

Oxigene outlines significant Q3 developments

WHI-05 and WHI-07: suitable development candidates as anti-HIV contraceptives

Parker Hughes Institute program yields potential new virucidal vaginal contraceptives

Clinical status update for oral influenza neuraminidase inhibitor

Bioavailability of new 5-LO inhibitor CJ-13610 in dogs and humans

Intrapulmonary delivery of insulin enhanced with Emisphere delivery agents

AHP highlights innovative new products at NYC conference

Gamma-secretase inhibitors as novel therapies for AD discussed at AAPS meeting

Microsponge formulation of 5-FU approved by FDA for actinic keratoses

Promising new colon-specific 5-ASA prodrug developed by U.S. and Korean scientists

InKine selects tradenames for CBP-1011

News from ICACI 2000: IL-4/IL-5 inhibitor exerts beneficial effects in models of atopic dermatitis

Nastech's intranasal apomorphine enters phase II for MED

Yeda prepares novel antiinflammatory and immunomodulating dipeptides

Inhaled liposomal IL-2 well tolerated in patients with lung metastases

Recent patent protects new macrocyclic perfluoroalkylamides and their use in diagnostics

Cyclin/cdk inhibitors synthesized and tested at Albany Molecular Research

Novel Roche compounds claimed for pain, urinary disorders and sexual dysfunction

CGRP antagonists described by Boehringer Ingelheim in recent patent

LHRH antagonists particularly useful in hormone-dependent cancer

Boehringer Ingelheim presents new group of inhibitors of inflammatory cytokines

Danish phase I trial of anti-CD4 MAb reported at ACR 2000 meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...